Castle Biosciences (CSTL) Other Operating Expenses (2020 - 2026)

For the trailing twelve months through Sep 30, 2026, Other Operating Expenses at Castle Biosciences was $67.15 million, down 22.8% year-over-year; for FY2025, it came in at $86.69 million, up 37.3% from FY2024.

• Annual Other Operating Expenses has increased for five consecutive years, with a five-year compound annual growth rate of 50.1% (FY2020 to FY2025).
• In prior years, Castle Biosciences' Other Operating Expenses was $63.15 million in FY2024 (+0.8%), $62.63 million in FY2023 (+79.6%), $34.88 million in FY2022 (+10.4%) and $31.6 million in FY2021 (+177.9%).
• The Q3 2026 figure stands as the highest quarterly Other Operating Expenses since Q1 2025.
• On a year-over-year basis, Other Operating Expenses increased in five of the last eight quarters, with growth averaging 15.6%.
• The strongest year-over-year quarter for Other Operating Expenses in the past five years was Q4 2021, with growth of 287.3%; the weakest was Q1 2026, with a decline of 59.3%.
• According to Business Quant data, Other Operating Expenses for the three prior quarters was $16.79 million (Q2 2026), $16.65 million (Q1 2026) and $15.79 million (Q4 2025).